Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
26 June 2013Website:
http://www.nanostring.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Tue, 25 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
NSTG Latest News
Life science applications specialist NanoString (NASDAQ: NSTG ), which provides tools for discovery and translation research, announced that it has entered into a credit agreement with its existing lenders. Driving the need for such an arrangement was a bankruptcy filing at the beginning of the week.
Investors looking at today's price action in NanoString (NASDAQ: NSTG ) stock ought to be shaking their heads in amazement. Indeed, after announcing the company would be filing for bankruptcy protection on Monday, many thought the story with NanoString was over.
NanoString Technologies (NASDAQ: NSTG ) stock is taking a beating on Monday after the company announced a voluntary Chapter 11 bankruptcy filing. NanoString Technologies notes that this bankruptcy filing is the result of its lost litigation battles against 10x Genomics.
Seattle-based publicly traded biotech company NanoString Technologies said in a filing Friday that it plans to cut about 50 positions, or 9% of its workforce.
SEATTLE--(BUSINESS WIRE)--NanoString to present at November conferences.
NanoString Technologies, Inc. (NASDAQ:NSTG ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Doug Farrell - IR Brad Gray - President and CEO Tom Bailey - CFO Conference Call Participants Marta Nazarovets - JPMorgan Kyle Boucher - TD Cowen Catherine Schulte - Baird Evan Stampler - Stifel Alexander Vukasin - Canaccord Genuity Operator Good afternoon. My name is Krista and I'll be your conference operator today.
While the top- and bottom-line numbers for NanoString (NSTG) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
In stock trading, shorting is seen as a high-risk, high-reward strategy. This approach involves borrowing stocks, selling them, and betting on their price dropping to make a profit.
According to NanoString (NSTG), SMI's unique ability to interrogate both RNA and proteins at ultra-high plex with subcellular resolution has made it a one-of-a-kind tool.
NanoString's (NSTG) nCounter Analysis System facilitates bulk tissue transcriptome profiling, revealing the intricacies of the immune response through the nCounter Human Organ Transplant Panel.
What type of business is NanoString Technologies?
NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.
What sector is NanoString Technologies in?
NanoString Technologies is in the Healthcare sector
What industry is NanoString Technologies in?
NanoString Technologies is in the Medical Instruments & Supplies industry
What country is NanoString Technologies from?
NanoString Technologies is headquartered in United States
When did NanoString Technologies go public?
NanoString Technologies initial public offering (IPO) was on 26 June 2013
What is NanoString Technologies website?
https://www.nanostring.com
Is NanoString Technologies in the S&P 500?
No, NanoString Technologies is not included in the S&P 500 index
Is NanoString Technologies in the NASDAQ 100?
No, NanoString Technologies is not included in the NASDAQ 100 index
Is NanoString Technologies in the Dow Jones?
No, NanoString Technologies is not included in the Dow Jones index
When does NanoString Technologies report earnings?
Next earnings report date is not announced yet